| 臺大學術典藏 |
2022-09-15T01:09:00Z |
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
|
Bang Y.-J.; Su W.-C.; Schuler M.; Nam D.-H.; Lim W.T.; Bauer T.M.; Azaro A.; Poon R.T.P.; Hong D.; Chia-Chi Lin; Akimov M.; Ghebremariam S.; Zhao S.; Giovannini M.; Ma B. |
| 臺大學術典藏 |
2022-08-19T00:20:47Z |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
|
Tak W.Y.; Yen C.-J.; Jeffers M.; Krissel H.; Kappeler C.; Rajagopalan P.; Hsieh W.-S.; Tay M.H.; Yeo W.; Park J.-W.; Poon R.T.P.; Rau K.-M.; CHIUN HSU; Yoon J.-H.; Lin C.-Y.; Choi H.J.; Heo J.; Lim H.Y. |
| 臺大學術典藏 |
2021-09-01T01:54:16Z |
Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma
|
Omata M.; Lesmana L.A.; Tateishi R.; Chen P.-J.; Lin S.-M.; Yoshida H.; Kudo M.; Lee J.M.; Choi B.I.; Poon R.T.P.; Shiina S.; ANN-LII CHENG; Jia J.-D.; Obi S.; Han K.H.; Jafri W.; Chow P.; Lim S.G.; Chawla Y.K.; Budihusodo U.; Gani R.A.; Lesmana C.R.; Putranto T.A.; Liaw Y.F.; Sarin S.K. |
| 臺大學術典藏 |
2021-09-01T01:54:04Z |
Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia
|
Han K.-H.; Kudo M.; Ye S.-L.; Choi J.Y.; Poon R.T.-P.; Seong J.; Park J.-W.; Ichida T.; Chung J.W.; Chow P.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:44Z |
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study
|
Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; Hsu C.-H.; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Avi?a J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:42:21Z |
Recent advances in the prevention of hepatocellular carcinoma recurrence
|
Lu L.-C.; ANN-LII CHENG; Poon R.T.P. |
| 臺大學術典藏 |
2021-08-31T06:29:46Z |
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
|
ANN-LII CHENG; Thongprasert S.; Lim H.Y.; Sukeepaisarnjaroen W.; Yang T.-S.; Wu C.-C.; Chao Y.; Chan S.L.; Kudo M.; Ikeda M.; Kang Y.-K.; Pan H.; Numata K.; Han G.; Balsara B.; Zhang Y.; Rodriguez A.-M.; Zhang Y.; Wang Y.; Poon R.T.P. |
| 臺大學術典藏 |
2021-07-03T03:34:45Z |
Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma
|
Omata M.; Lesmana L.A.; Tateishi R.; PEI-JER CHEN; Lin S.-M.; Yoshida H.; Kudo M.; Lee J.M.; Choi B.I.; Poon R.T.P.; Shiina S.; Cheng A.L.; Jia J.-D.; Obi S.; Han K.H.; Jafri W.; Chow P.; Lim S.G.; Chawla Y.K.; Budihusodo U.; Gani R.A.; Lesmana C.R.; Putranto T.A.; Liaw Y.F.; Sarin S.K. |
| 臺大學術典藏 |
2021-07-03T03:34:20Z |
Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: The emerging role for radioembolization using yttrium-90
|
Lau W.-Y.; Sangro B.; PEI-JER CHEN; Cheng S.-Q.; Chow P.; Lee R.-C.; Leung T.; Han K.-H.; Poon R.T.P. |
| 臺大學術典藏 |
2021-07-03T03:33:48Z |
A phase I/II multicenter study of single-agent foretinib as first-line therapy in patients with advanced hepatocellular carcinoma
|
Yau T.C.C.; Lencioni R.; Sukeepaisarnjaroen W.; Chao Y.; Yen C.-J.; Lausoontornsiri W.; PEI-JER CHEN; Sanpajit T.; Camp A.; Cox D.S.; Gagnon R.C.; Liu Y.; Raffensperger K.E.; Kulkarni D.A.; Kallender H.; Ottesen L.H.; Poon R.T.P.; Bottaro D.P. |
| 臺大學術典藏 |
2021-03-15T07:44:47Z |
Recent advances in the prevention of hepatocellular carcinoma recurrence
|
LI-CHUN LU; Cheng A.-L.; Poon R.T.P. |
| 臺大學術典藏 |
2020-05-25T07:35:01Z |
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
|
Chia-Chi Lin; Akimov M; Ghebremariam S; Hong D; Poon R.T.P; Azaro A; Lim W.T; Bauer T.M; Nam D.-H; Schuler M; Su W.-C; Bang Y.-J; Zhao S; Giovannini M; Ma B. |
| 臺大學術典藏 |
2020-04-10T12:51:06Z |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
|
Lim H.Y.; Heo J.; Choi H.J.; Lin C.-Y.; Yoon J.-H.; Chiun Hsu; Rau K.-M.; Poon R.T.P.; Yeo W.; Park J.-W.; Tay M.H.; Hsieh W.-S.; Kappeler C.; Rajagopalan P.; Krissel H.; Jeffers M.; Yen C.-J.; Tak W.Y. |
| 臺大學術典藏 |
2020-02-19T09:33:43Z |
Surgery for intermediate and advanced hepatocellular carcinoma: A consensus report from the 5th Asia-pacific primary liver cancer expert meeting (apple 2014)
|
MING-CHIH HO; Hasegawa K.; Chen X.-P.; Nagano H.; Lee Y.-J.; Chau G.-Y.; Zhou J.; Wang C.-C.; Choi Y.R.; Poon R.T.-P.; Kokudo N. |
| 國立成功大學 |
2020 |
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
|
Bang, Y.-J.;Su, W.-C.;Schuler, M.;Nam, D.-H.;Lim, W.T.;Bauer, T.M.;Azaro, Azaro A.;Poon, R.T.P.;Hong, D.;Lin, C.-C.;Akimov, M.;Ghebremariam, S.;Zhao, S.;Giovannini, M.;Ma, B. |
| 臺大學術典藏 |
2018-09-10T08:13:48Z |
Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma
|
Omata, M.;Lesmana, L.A.;Tateishi, R.;Chen, P.-J.;Lin, S.-M.;Yoshida, H.;Kudo, M.;Lee, J.M.;Choi, B.I.;Poon, R.T.P.;Shiina, S.;Cheng, A.L.;Jia, J.-D.;Obi, S.;Han, K.H.;Jafri, W.;Chow, P.;Lim, S.G.;Chawla, Y.K.;Budihusodo, U.;Gani, R.A.;Lesmana, C.R.;Putranto, T.A.;Liaw, Y.F.;Sarin, S.K.; PEI-JER CHEN; ANN-LII CHENG |
| 國立成功大學 |
2012-03 |
A PHASE I/II STUDY OF FORETINIB, AN ORAL MULTIKINASE INHIBITOR TARGETING MET, RON, AXL, TIE-2 AND VEGFR IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
|
Yau, T.; Yen, C. -J.; Chen, P. -J.; Chau, Y.; Lencioni, R.; Kallender, H.; Ottesen, L. H.; Poon, R. T. -P. |
